CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (NASDAQ:CERS) announced today the receipt of a $5 million cash milestone payment from BioOne Corporation. The milestone payment was prompted by Cerus’ recent receipt of CE mark regulatory approval for the INTERCEPT Blood System for plasma in Europe. In addition to the cash payment, Cerus expects to receive an additional milestone payment of BioOne preferred stock worth $5 million in early 2007 pursuant to the terms of its agreement with BioOne. Upon receipt of the cash milestone payment, Cerus forwarded $0.5 million to Baxter Healthcare Corporation in accordance with an agreement relating to the BioOne commercialization rights.
